Liraglutide in obesity: a guide to its use in the EU

[1]  L. Aronne,et al.  Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria , 2015 .

[2]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[3]  L. Scott.  Liraglutide: A Review of Its Use in the Management of Obesity , 2015, Drugs.

[4]  A. Astrup,et al.  Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE™ Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial , 2015 .

[5]  L. Seoane,et al.  Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss , 2014, Drug design, development and therapy.

[6]  L. Scott.  Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus , 2014, Drugs.

[7]  L. Aronne,et al.  Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2014, International Journal of Obesity.

[8]  M. Shin.  Management of Overweight and Obesity: Review of the "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults" , 2014 .

[9]  B. Sloth,et al.  Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults , 2013, International Journal of Obesity.

[10]  T. Wadden,et al.  Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. , 2013, Sleep.

[11]  G. Bray.  Why do we need drugs to treat the patient with obesity? , 2013, Obesity.

[12]  T. Funahashi,et al.  Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes , 2012, Cardiovascular Diabetology.

[13]  C. Kapitza,et al.  Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. , 2012, Diabetes research and clinical practice.

[14]  T. Funahashi,et al.  Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes , 2011, Cardiovascular Diabetology.

[15]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[16]  S. Boyle,et al.  Understanding the relationship between weight loss, emotional well-being and health-related quality of life in patients attending a specialist obesity weight management service , 2011, Journal of health psychology.

[17]  L. Hegedüs,et al.  GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. , 2011, The Journal of clinical endocrinology and metabolism.

[18]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[19]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.

[20]  D. Allison,et al.  Waist Circumference and Cardiometabolic Risk , 2007, Diabetes Care.

[21]  N. Bansback,et al.  The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis , 2009, BMC Public Health.